Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Silexion Therapeutics CorpSLXN · Entity 8506 | Director | February 20, 2026 | February 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Silexion Therapeutics Corp
Report date February 20, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Guangzhou Sino-Israel Biotech Fund | 25,399 |
Reported balance
After 2026-02-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 9,091 · Balance 25,399 F1: The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer. The grant was approved by the Issuer's board of directors. F2: The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2036-02-12 | IndirectBy Guangzhou Sino-Israel Biotech Fund | 10,685 |
Reported balance
After 2026-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-20 · Grant · Acquired 10,685 · Balance 10,685 F3: The transaction reported in this row consists of the grant to GIBF by the Issuer of options to purchase ordinary shares, for director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer, which grant was approved by the Issuer's board of directors. F4: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. F2: The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2035-02-09 | IndirectBy Guangzhou Sino-Israel Biotech Fund | 1,872 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,872 F5: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F2: The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer. The grant was approved by the Issuer's board of directors.
F2: The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.
F3: The transaction reported in this row consists of the grant to GIBF by the Issuer of options to purchase ordinary shares, for director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer, which grant was approved by the Issuer's board of directors.
F4: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
F5: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2026 Filed Feb 25, 2026 16:23 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantStock Option (right to buy ordinary shares) · Derivative | 10,685 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001178913-26-000644 · zk2634447.xml · derivative · entry 2 Noy Shlomo · CIK 0002033211 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Guangzhou Sino-Israel Biotech Fund Disclosed balance after: 10,685 Underlying: Ordinary Shares · 10,685 shares Expires 2036-02-12 F3 · kind: The transaction reported in this row consists of the grant to GIBF by the Issuer of options to purchase ordinary shares, for director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer, which grant was approved by the Issuer's board of directors. F4 · derivative.exercise_date: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. F4 · derivative.expiration_date: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. F2 · ownership.nature: The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein. Read SEC document |
| February 20, 2026 Filed Feb 25, 2026 16:23 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantOrdinary Shares | 9,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-000644 · zk2634447.xml · nonDerivative · entry 1 Noy Shlomo · CIK 0002033211 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Guangzhou Sino-Israel Biotech Fund Disclosed balance after: 25,399 F1 · kind: The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer. The grant was approved by the Issuer's board of directors. F2 · ownership.nature: The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein. Read SEC document |
| February 09, 2025 Filed Dec 31, 2025 13:07 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantStock Option (right to buy ordinary shares) · Derivative | 1,872 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001178913-25-004147 · zk2534152.xml · derivative · entry 3 Noy Shlomo · CIK 0002033211 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Guangzhou Sino-Israel Biotech Fund Disclosed balance after: 1,872 Underlying: Ordinary Shares · 1,872 shares Expires 2035-02-09 F6 · security: Represents stock options granted by the Issuer to GIBF for director services provided by the Reporting Person and Avner Lushi (each, with respect to half of the options). F7 · derivative.exercise_price: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F7 · shares: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F8 · derivative.exercise_date: All of the stock options reported in this row vest (and become exercisable) on the first anniversary of the date of grant (i.e., on February 9, 2026), subject to the Reporting Person's or Mr. Lushi's (each, with respect to half of the options) continued service through such date. F7 · derivative.underlying_shares: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F7 · balance_after: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F3 · ownership.nature: The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this line by virtue of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein. Read SEC document |
| February 09, 2025 Filed Dec 31, 2025 13:07 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantOrdinary Shares | 1,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-25-004147 · zk2534152.xml · nonDerivative · entry 1 Noy Shlomo · CIK 0002033211 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Guangzhou Sino-Israel Biotech Fund Disclosed balance after: 1,587 F1 · security: Represents ordinary shares underlying RSUs granted to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer for director services provided by the Reporting Person and Avner Lushi. The shares subject to this award vest in full on the first anniversary of the grant date, subject to the Reporting Person's or Mr. Lushi's (each, with respect to half of the shares) continued service through such date. F1 · kind: Represents ordinary shares underlying RSUs granted to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer for director services provided by the Reporting Person and Avner Lushi. The shares subject to this award vest in full on the first anniversary of the grant date, subject to the Reporting Person's or Mr. Lushi's (each, with respect to half of the shares) continued service through such date. F2 · shares: The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F2 · balance_after: The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F3 · ownership.nature: The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this line by virtue of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.